How to Help Your Patients Find Padcev in Stock: A Provider's Guide

Prescribing Padcev (enfortumab vedotin-ejfv) is one step — but ensuring your patient can actually receive it on schedule is another challenge entirely. From insurance prior authorization to infusion center logistics, oncology practices must navigate a complex system to get this life-saving treatment into patients' hands on time.

This practical guide walks through actionable steps your team can take to minimize delays and ensure your patients receive Padcev without unnecessary interruptions.

Step 1: Enroll Patients in PADCEV Support Solutions at Prescription Time

The single most impactful step you can take is to enroll patients in PADCEV Support Solutions at the time of prescription — not after an insurance denial. PADCEV Support Solutions (1-888-402-0627) provides:

Benefits investigation (BI) to evaluate the patient's insurance coverage for Padcev

PA form retrieval and submission support

Appeals support including required documentation

Copay assistance enrollment for commercially insured patients ($5/dose, up to $25,000/year)

Patient Assistance Program (PAP) for uninsured patients who meet financial eligibility

Coding and billing support for your practice's billing team

Enrollment is available via fax (1-877-747-6843) or through the online Prescriber Portal at astellaspharmasupportsolutions.com.

Step 2: Submit a Complete Prior Authorization Package

Incomplete PA submissions are the most common source of delay. Build a standardized PA packet for Padcev that includes:

Pathology report confirming urothelial carcinoma (bladder, ureter, renal pelvis, or urethra)

Staging documentation (AJCC stage III/IV or metastatic)

ECOG performance status

Prior treatment history (for monotherapy indication: prior PD-1/L1 inhibitor + platinum chemotherapy)

Cisplatin eligibility documentation (GFR, hearing status, neuropathy, ECOG)

Baseline HbA1c and blood glucose (required monitoring per label)

Step 3: Coordinate Drug Ordering With Your Infusion Center

Padcev is a high-cost specialty biologic. Most infusion centers order it on a per-patient basis rather than maintaining standing stock. Best practices for infusion center coordination:

Confirm PA approval before scheduling infusion appointments

Allow 3-5 business days lead time for the infusion center to order and receive Padcev vials

Calculate dose in advance (1.25 mg/kg, max 125 mg for patients ≥100 kg) so correct vial quantities are ordered

Ensure infusion center has hazardous drug handling protocols in place (Padcev is classified as hazardous)

Step 4: Identify Alternative Infusion Sites for Patients With Access Barriers

For patients in rural areas or those who have limited access to your facility, consider:

Referral to a closer NCI-designated cancer center or community oncology practice experienced with ADCs

Coordinating shared-care protocols with a regional community hospital or infusion center

Telehealth-based monitoring visits combined with local infusion center administration

Transportation assistance through cancer center social work or Patient Connect programs

39,483+ patients found their medications in stock

39K+

Find Padcev In Stock Today →

Step 5: Use medfinder to Locate Facilities for Your Patients

medfinder for providers is a patient access service that contacts pharmacies and infusion facilities on your patient's behalf to determine which locations near them can fill or administer their prescribed medication. Results are texted directly to the patient, saving your staff hours of coordination calls. This is particularly valuable when a patient's primary infusion center has scheduling gaps or Padcev isn't available on their appointment date.

Step 6: Proactively Address Dose Delays and Modifications

Dose delays are built into the Padcev management algorithm for toxicity. Having a clear protocol helps your team act quickly:

First dose reduction: 1 mg/kg (max 100 mg)

Second dose reduction: 0.75 mg/kg (max 75 mg)

Third dose reduction: 0.5 mg/kg (max 50 mg)

For a deeper dive into PA strategy and clinical monitoring requirements, see: Padcev Access Challenges: What Providers and Prescribers Need to Know in 2026.